Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target

The SON-1010 studies have together enrolled 61 subjects, to date, as dose escalation continues in SB101 and SB221 at higher levelsPatients have received up to 25 cycles of SON-1010 as monotherapy and 10

Related Keywords

United States ,Pankaj Mohan ,Jack Yauch ,Robert Wenham ,Richard Kenney ,Sonnet Biotherapeutics Holdings Inc ,Nasdaq ,Solebury Strategic Communications ,Exchange Commission ,Oncology At Moffitt Cancer Center ,Genentech ,Company Or Sonnet ,Roche Group ,Securities Exchange ,Fully Human Albumin Binding ,Secreted Protein Acidic ,Safety Review Committees ,Chief Medical ,Response Evaluation Criteria ,Solid Tumors ,Moffitt Cancer Center ,Lead Principal Investigator ,Sonnet Founder ,Chief Executive ,Secreted Protein ,Programed Death Ligand ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,Ihr Portfolio ,